スウェーデンの研究チームは、ヒト幹細胞からインスリン産生細胞を作製し、それをマウスに移植することで糖尿病の症状を改善することに成功した。これらの細胞は眼内移植後に成熟し、数ヶ月間にわたって血糖調節機能を維持した。この研究成果は『Stem Cell Reports』誌に掲載された。
カロリンスカ研究所の科学者らは、複数のヒト多能性幹細胞株から膵島を作製するための改良プロトコルを開発した。この手法では、洗練された培養条件と三次元クラスターを用いることで、望ましくない細胞種の発生を抑制し、グルコース応答性を高めている。
AIによるレポート AIによって生成された画像
A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.
A team led by Leonardo Ferreira at the Medical University of South Carolina is developing a novel therapy combining lab-made insulin-producing cells with engineered immune cells to protect them. Funded by $1 million from Breakthrough T1D, the approach aims to restore beta cell function without immunosuppressive drugs. This strategy builds on prior research and targets all stages of the disease.
AIによるレポート
Researchers have identified why living at high altitudes reduces diabetes risk: red blood cells absorb excess glucose in low-oxygen conditions. This metabolic shift lowers blood sugar levels, as shown in mouse experiments. A new drug mimicking this effect reversed diabetes in mice, suggesting potential treatments.
Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.
AIによるレポート 事実確認済み
Researchers at the University of California, Riverside say they have developed a flexible, battery-powered gel patch that generates oxygen inside hard-to-heal wounds—an approach aimed at countering deep-tissue oxygen deprivation that can stall recovery and contribute to amputations. In experiments in diabetic and older mice, the team reported that wounds that often remained open—and were sometimes fatal—closed in about 23 days when treated with the oxygen-generating patch.